Evidence map›Paper›PMID 31324387›Full record

ArticleNeuropeptides2019

Prokinetic effects of the neurokinin NK2 receptor agonist [Lys

Nadia M J Rupniak, Mary A Katofiasc, Lesley Marson, Daniel J Ricca, Karl B Thor, Edward C Burgard

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropeptides, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Recent Developments in On-Demand Voiding Therapies.The Journal of pharmacology and experimental therapeutics · 2024
    Review
  2. [LysJournal of basic and clinical physiology and pharmacology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Nadia M J RupniakDignify Therapeutics LLC, 2 Davis Drive, P.O. Box 13169, Research Triangle Park, NC 27709, USA. Electronic address: nrupniak@dignifytherapeutics.com.
Mary A KatofiascDignify Therapeutics LLC, 2 Davis Drive, P.O. Box 13169, Research Triangle Park, NC 27709, USA.
Lesley MarsonDignify Therapeutics LLC, 2 Davis Drive, P.O. Box 13169, Research Triangle Park, NC 27709, USA.
Daniel J RiccaDignify Therapeutics LLC, 2 Davis Drive, P.O. Box 13169, Research Triangle Park, NC 27709, USA.
Karl B ThorDignify Therapeutics LLC, 2 Davis Drive, P.O. Box 13169, Research Triangle Park, NC 27709, USA.
Edward C BurgardDignify Therapeutics LLC, 2 Davis Drive, P.O. Box 13169, Research Triangle Park, NC 27709, USA.
Dignify Therapeutics (United States) · USTriangle · US

Funding

Development of a first-in-class therapeutic for producing 'on-demand' voidingR44DK112437 · NIDDK · DIGNIFY THERAPEUTICS, LLC · PI THOR, KARL B · 2017 to 2019
$2.3M
NIDDK NIH HHS R44 DK112437
6 · The paper itself

Abstract

The effects of the neurokinin NK2 receptor agonist [Lys

Indexed as

AnimalsColonDefecationIndolesPiperidinesPressureReceptors, Neurokinin-2RectumSwineSwine, MiniatureUrinary BladderUrinationGR 159897IndolesPiperidinesReceptors, Neurokinin-2DefecationIntranasalMinipigNK2 receptor agonistSublingualUrination

Identifiers

PMID31324387
PMCPMC6739136
OpenAlexW2961910917

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.